Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1904 - Incidence of Imatinib Resistance in Chronic Myeloid Leukemia (CML) Patients: Experience from Resource Poor Centre of Eastern India

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Leukaemias

Presenters

Debmalya Bhattacharyya

Citation

Annals of Oncology (2019) 30 (suppl_5): v435-v448. 10.1093/annonc/mdz251

Authors

D. Bhattacharyya1, R. Ghosh2, P. Gupta2, A. Gupta2, S. Roychoudhury3, S. Nath3

Author affiliations

  • 1 Hemato-oncology, Saroj Gupta Cancer Centre & Research Institute, 700063 - Kolkata/IN
  • 2 Hemato-oncology, Saroj Gupta Cancer Centre and Research Institute, 700063 - Kolkata/IN
  • 3 Clinical Research, Saroj Gupta Cancer Centre and Research Institute, 700063 - Kolkata/IN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1904

Background

The management of Chronic Myeloid Leukemia (CML) has undergone a paradigm shift with advent of the tyrosine kinase inhibitor (TKI), namely imatinib. Despite a high remission rate, a significant proportion of patients showed resistance and/or intolerance to imatinib therapy, be it primary or secondary. However, the scenario of resistance along with the prevalence and clinical route of CML in the Eastern part of India remains elusive. To observe the incidence of resistance to TKI after years of therapy, we performed a study in a tertiary cancer care centre, serving patients from Eastern Indian states as well as neighbor countries like Bangladesh and Bhutan. Based on the CML cases registered at the centre for the last 13 years, we performed a longitudinal assessment of the disease history and molecular management to portray the incidence of imatinib resistance in CML patients.

Methods

The methods in schematic are described below: No. of CML cases with disease history ↓ Patients showing loss of Major Molecular Response (MMR), detected by Real-Time quantitative PCR ↓ Mutation analysis in BCR-ABL kinase domain (KD) (by Sanger sequencing) ↓ Calculation of type and incidence of KD mutation ↓ The survival analyses performed by Kaplan-Meier analysis.

Results

The results are presented in tabular form as below:.Table: 1098P

No. of registered CML cases (2005-2017)Median period of Imatinib treatmentNo. of patients showing Loss of MMR (BCR-ABL >1.0%)No. of patients undergoing BCR-ABL KD mutation testing (% affordability)No. of patients showing BCR-ABL KD mutationPatients with Imatinib failure but no detectable BCR-ABL KD mutation
98626 months10120 (20%)11 (55% of resistant pool)9 (45% of resistant pool)

After years of therapy, KD mutations are seen in 55% of imatinib-resistant patients. The survival analysis showed significant difference between treatment-sensitive and –resistant pools.

Conclusions

The incidence of imatinib resistance has been increasingly detected in Eastern-Indian region after long term therapy with imatinib. However, the full scenario could not be depicted due to resource constraints. More numbers of patients are to be tested to achieve robust evidence.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.